Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as an injectable solution for intravenous use. It enables myocardial perfusion imaging to assess coronary artery disease in patients undergoing cardiac stress testing.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Myoview is a radiopharmaceutical used in cardiac imaging to evaluate myocardial blood flow and detect coronary artery disease.

- Myocardial perfusion imaging: provides quantitative assessment of regional blood flow to the heart muscle. - Detection of coronary artery disease: helps identify obstructive lesions by comparing stress and rest perfusion. - Stress and rest cardiac SPECT: enables visualization of perfusion differences under pharmacologic or exercise stress and at rest.

Myoview may cause a range of adverse reactions following administration.

Common Side Effects: - Nausea: mild to moderate discomfort after injection. - Flushing: transient warmth or redness of the skin. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Injection‑site pain or irritation. - Mild hypotension.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of airway swelling, rash, or shock. - Life‑threatening arrhythmia: abnormal heart rhythm requiring immediate care. - Marked hypotension: sudden drop in blood pressure. - Myocardial infarction: rare occurrence of heart attack post‑administration. - Pulmonary edema: fluid accumulation in the lungs. - Death: extremely rare but reported in severe reactions.

Prior to Myoview administration, clinicians should consider several safety measures.

- Patient assessment: evaluate renal function and overall cardiac status. - Contraindications: avoid in individuals with known hypersensitivity to tetrofosmin or its excipients. - Pregnancy: use only if essential, as safety data are limited. - Breastfeeding: discontinue nursing or discontinue the drug, based on clinical judgment. - Drug interactions: review concurrent medications that affect myocardial blood flow. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Myoview may interact with other agents that influence myocardial perfusion or radiotracer distribution.

Major Interactions (Avoid): - Dipyridamole stress agents: concurrent use can alter tracer uptake. - Other nuclear imaging agents: administration within 24 hours may cause cross‑interference. - High‑dose caffeine: may blunt stress‑induced perfusion changes.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may reduce stress‑induced heart rate response. - Calcium channel blockers: can modify coronary vasodilation. - Nitrates: may affect myocardial blood flow patterns. - Antihypertensives: monitor blood pressure during imaging. - ACE inhibitors or ARBs: observe for altered perfusion signals.